Evidence of house dust mite immunotherapy in paediatric asthma: a review

Abstract

Asthma is a prevalent chronic respiratory condition in children, often exacerbated by allergic reactions, with house dust mites (HDMs) being a significant trigger. Traditional asthma management primarily involves inhaled corticosteroids and bronchodilators, which do not address the underlying allergic mechanisms. Allergen immunotherapy, including subcutaneous and sublingual immunotherapy (SLIT), has emerged as a strategy to induce immune tolerance to allergens. This review evaluates the efficacy of HDM immunotherapy in paediatric asthma, focusing on reductions in asthma exacerbations, improvements in lung function, decreases in medication use, and enhancements in quality of life (QoL). The review highlights that both subcutaneous immunotherapy (SCIT) and SLIT significantly reduce asthma exacerbations in children, with SCIT showing superior efficacy in lung function improvement. Combination therapies, particularly SCIT with biologics, demonstrate enhanced outcomes, including exacerbations and medication use reductions. SCIT has also been shown to improve lung function more effectively than SLIT, particularly in children with high baseline levels of HDM-specific IgE. In terms of safety, both SCIT and SLIT are generally well-tolerated, though SCIT is associated with more localized and systemic reactions, which can be mitigated by combination with biologics. Furthermore, HDM immunotherapy significantly enhances the QoL in paediatric patients by reducing asthma symptoms and improving sleep, leading to long-lasting benefits. Despite these positive outcomes, there remain gaps in knowledge, particularly regarding the optimal duration of therapy and long-term effects post-treatment. Future research should standardize treatment protocols, explore personalized approaches, and investigate the long-term sustainability of treatment benefits to fully optimize the use of HDM immunotherapy in paediatric asthma.

Keywords

Paediatrics / asthma / immunotherapy / house dust mite (HDM) / subcutaneous immunotherapy (SCIT) / sublingual immunotherapy (SLIT) / quality of life / adverse effects

References

[1] Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019; 7: 246.

[2] Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev. 1999: CD003274.

[3] Miraglia Del Giudice M, Licari A, Brambilla I, Tosca MA, Ciprandi G. Allergen Immunotherapy in Pediatric Asthma: A Pragmatic Point of View. Children (Basel). 2020; 7: 58.

[4] Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014; 7: 12.

[5] Andersson E, Löfvendahl S, Olofsson S, Wahlberg K, Bjermer L, Tornling G, et al. Disease burden and unmet need for acute allergic reactions - A patient perspective. World Allergy Organ J. 2024; 17: 100896.

[6] Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy. 2005; 60: 1357- 60.

[7] Lommatzsch M, Stoll P. Novel strategies for the treatment of asthma. Allergo J Int. 2016; 25: 11-7.

[8] Orlovic M, Tzelis D, Guerra I, Bar-Katz V, Woolley N, Bray H, et al. Environmental, healthcare and societal impacts of asthma: a UK model-based assessment. ERJ Open Res. 2024; 10: 00577-2023.

[9] Kuder MM, Clark M, Cooley C, Prieto-Centurion V, Danley A, Riley I, et al. A Systematic Review of the Effect of Physical Activity on Asthma Outcomes. J Allergy Clin Immunol Pract. 2021; 9: 3407-21.e8.

[10] Alomary SA, Althagafi WA, Al Madani AJ, Adam IF, Elsherif OE, Al-Abdullaah AA, et al. The burden of asthma among children and adolescents in Saudi Arabia: A national cross-sectional survey. J Allergy Clin Immunol Glob. 2022; 1: 241-7.

[11] Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. ; U-BIOPRED Study Group. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015; 46: 1322-33.

[12] Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017; 3: 1.

[13] Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015; 136: 38-48.

[14] Global Strategy for Asthma Management and Prevention (2023 update) [Internet]. Global Initiative for Asthma; c2023 [cited 2024 Jun 1]. Available from: https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf

[15] Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019; 74: 855-73.

[16] Klain A, Senatore AA, Licari A, Galletta F, Bettini I, Tomei L, et al. The Prevention of House Dust Mite Allergies in Pediatric Asthma. Children (Basel). 2024; 11: 469.

[17] Murray CS, Foden P, Sumner H, Shepley E, Custovic A, Simpson A. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers. Am J Respir Crit Care Med. 2017; 196: 150-8.

[18] Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 31: 1-101.

[19] Berce V, Cugmas M, Čopi S, Koren B, Tomazin M, Hojnik T. Evaluation and Comparison of the Efficacy of Subcutaneous and Sublingual Immunotherapy for the Treatment of Allergic Asthma in Children. Children (Basel). 2024; 11: 692.

[20] Long C, Sun C, Lin H, Gao X, Qu Z. Efficacy and safety of subcutaneous immunotherapy combined with omalizumab in children with dust mite-induced asthma. J Asthma. 2024; 61: 1561-70.

[21] Bożek A, Fischer A, Bogacz-Piaseczynska A, Canonica GW. Adding a biologic to allergen immunotherapy increases treatment efficacy. ERJ Open Res. 2023; 9: 00639-2022.

[22] Shen W, Zhou Q, Zhang Q, Han L, Chen L, Li X, et al. Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma. Int Forum Allergy Rhinol. 2025; 15: 208-11.

[23] Nogami K, Nagao M, Takase T, Yasuda Y, Yamada S, Matsunaga M, et al. House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma. Children (Basel). 2022; 9: 487.

[24] Zheng C, Xu H, Huang S, Chen Z. Efficacy and safety of subcutaneous immunotherapy in asthmatic children allergic to house dust mite: a meta-analysis and systematic review. Front Pediatr. 2023; 11: 1137478.

[25] Mite Asthma Pediatric Immunotherapy Trial (MAPIT) [Internet]. [cited 2024 Jun 1]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03654976

[26] Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, et al. Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study). Lancet Reg Health Eur. 2024; 41: 100915.

[27] Schuster A, Caimmi D, Nolte H, Novakova S, Mikler J, Foss-Skiftesvik MH, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial. Lancet Reg Health Eur. 2025; 48: 101136.

[28] Bozek A, Rogala B, Miodonska M, Canonica GW. Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma. J Asthma. 2024; 61: 532-8.

[29] Jutel M, Klimek L, Richter H, Brüggenjürgen B, Vogelberg C. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study. Allergy. 2024; 79: 1042-51.

[30] Tempels-Pavlica Ž, Aarts MCJ, Welsing PMJ, van der Meer AN, van der Zwan LP, Uss E, et al. House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice. Front Allergy. 2024; 5: 1355324.

[31] Bulbul L, Nursoy MA. Is It Possible to Predict Systemic Adverse Effects in Subcutaneous Allergen Immunotherapy? Single-Center Experience. Int Arch Allergy Immunol. 2024; 185: 1179-89.

[32] Trusova OV, Mizernitskiy YL, Trofimov VI, Kamaev AV, Platonova NB. The impact of allergen-specific immunotherapy with house dust mite allergens on the quality of life in children with bronchial asthma. Russ Bull Perinatol Pediatr. 2023; 68: 32-40. Russian.

[33] Garrido-Fernández S, Fernández DG, López GS, Mar Escribano Rodríguez MD, Delgado VM, Iglesias-Souto J, et al. Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy. Immunotherapy. 2024; 16: 693-704.

[34] Farraia M, Paciência I, Castro Mendes F, Cavaleiro Rufo J, H Shamji M, Agache I, et al. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma. Allergy. 2022; 77: 2688-98.

[35] Finegold I, Dockhorn RJ, Ein D, Dolen WK, Oppenheimer J, Potter LH. Immunotherapy throughout the decades: from Noon to now. Ann Allergy Asthma Immunol. 2010; 105: 328-36.

[36] Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach W. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol. 2012; 109: 274-8.

[37] Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, et al. ; DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013; 24: 427-33.